Last10K.com

Bristol Myers Squibb Co (BMY) SEC Filing 10-Q Quarterly report for the period ending Saturday, March 31, 2018

Bristol Myers Squibb Co

CIK: 14272 Ticker: BMY


Exhibit 99.1
bmslogoq12018.jpg
Bristol-Myers Squibb Reports First Quarter Financial Results

Increases First Quarter Revenues 5% to $5.2 Billion
Posts First Quarter GAAP EPS of $0.91 and Non-GAAP EPS of $0.94
Achieves Important Clinical and Regulatory Milestones in Oncology
Opdivo plus Yervoy Approved in the U.S. for Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma
Opdivo Four-Week Dosing Approved in the U.S. and Europe
Applications for Opdivo plus Yervoy for Previously Treated Patients with MSI-H or dMMR Metastatic Colorectal Cancer and Opdivo for Previously Treated Patients with Small Cell Lung Cancer Accepted for Priority Reviews in the U.S.
Presents Important New Data on Immuno-Oncology Portfolio at AACR Including Phase 3 Data for Opdivo plus Yervoy in First-Line Advanced Non-Small Cell Lung Cancer Patients with High Tumor Mutational Burden
Announces Strategic Collaborations with Nektar Therapeutics, Janssen Pharmaceuticals and Illumina, Inc.
Updates 2018 GAAP and Non-GAAP EPS Guidance

(NEW YORK, April 26, 2018)
- Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the first quarter of 2018 which were highlighted by strong sales for Opdivo, Eliquis, and Orencia, important regulatory progress in Immuno-Oncology and strategic business development transactions.

“We delivered strong commercial performance with continued growth for our key franchises, Opdivo and Eliquis, and obtained FDA approval for Opdivo plus Yervoy in renal cell carcinoma, a disease with high unmet need which represents an important opportunity for the company,” said Giovanni Caforio, M.D., chairman and chief executive officer, Bristol-Myers Squibb. “I am confident that strong commercial execution, upcoming Phase 3 readouts across our oncology pipeline and continued strategic use of business development position us well for future growth.”

 
First Quarter
$ amounts in millions, except per share amounts
 
 
 
 
 
 
2018
 
2017
 
Change
Total Revenues
$
5,193

 
$
4,929

 
5
 %
GAAP Diluted EPS
0.91

 
0.94

 
(3
)%
Non-GAAP Diluted EPS
0.94

 
0.84

 
12
 %


1


The following information was filed by Bristol Myers Squibb Co (BMY) on Thursday, April 26, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Bristol Myers Squibb Co's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Bristol Myers Squibb Co.

Continue

Assess how Bristol Myers Squibb Co's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Bristol Myers Squibb Co's Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
M & A
Other
Filter Subcategory:
All
Expense
Cash Flow
Product
Geography
Dividend
Income
Other
Inside Bristol Myers Squibb Co's 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Consolidated Balance Sheets (unaudited)
Consolidated Statements Of Cash Flows (unaudited)
Consolidated Statements Of Comprehensive Income (unaudited)
Consolidated Statements Of Earnings (unaudited)
Accrued Liabilities
Accrued Liabilities (details)
Accrued Liabilities (tables)
Alliances
Alliances (details)
Alliances (tables)
Basis Of Presentation (new Accounting Pronouncements) (details)
Basis Of Presentation (policies)
Basis Of Presentation Recently Adopted Accounting Standards (tables)
Business Segment Information
Divestitures (details)
Divestitures (notes)
Divestitures Divestitures (tables)
Earnings Per Share
Earnings Per Share (details)
Earnings Per Share (tables)
Equity
Equity (changes In Equity) (details)
Equity (other Comprehensive Income/(loss)) (details)
Equity (tables)
Financial Instruments And Fair Value Measurements
Financial Instruments And Fair Value Measurements (fair Value Measurement) (details)
Financial Instruments And Fair Value Measurements (available-for-sale) (details)
Financial Instruments And Fair Value Measurements (debt) (details)
Financial Instruments And Fair Value Measurements (derivatives And Hedging) (details)
Financial Instruments And Fair Value Measurements (tables)
Financial Instruments And Fair Value Measurements Gain/(loss) On Hedging Instrument (tables)
Income Taxes
Income Taxes (details)
Income Taxes (tables)
Inventories
Inventories (details)
Inventories (tables)
Legal Proceedings And Contingencies
Legal Proceedings And Contingencies (details)
Other Income (net)
Other Income (net) (details)
Other Income (net) (tables)
Other Intangible Assets
Other Intangible Assets (details)
Other Intangible Assets (tables)
Pension And Postretirement Benefit Plans
Pension And Postretirement Benefit Plans (details)
Pension And Postretirement Benefit Plans (tables)
Property, Plant And Equipment
Property, Plant And Equipment (details)
Property, Plant And Equipment (tables)
Receivables
Receivables (details)
Receivables (tables)
Restructuring
Restructuring (details)
Restructuring (tables)
Revenue Recognition (details)
Revenue Recognition (tables)
Revenue Recognition Disaggregation Of Revenue (details)
Revenue Recognition Revenue Recognition (notes)
Ticker: BMY
CIK: 14272
Form Type: 10-Q Quarterly Report
Accession Number: 0000014272-18-000117
Submitted to the SEC: Thu Apr 26 2018 12:08:19 PM EST
Accepted by the SEC: Thu Apr 26 2018
Period: Saturday, March 31, 2018
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/bmy/0000014272-18-000117.htm